undamentalytics Newsletter
Sign in

DBV Technologies S.a. (DBVT) stock

Add to watchlist

Add holding +

NASDAQ: DBVT Nasdaq Biotechnology Next results ~January 27, 2027

E Fundamentals grade

DBV Technologies S.a. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for DBV Technologies S.a. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

DBV Technologies S.a. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 7 sales by directors and officers, last 12 monthsInsider trades
  • Funds34 adding, 34 cuttingOf 12 active managers that changed their stake, 5 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter DBV Technologies files

Where DBV Technologies S.a. stands after its latest 10-Q

DBV Technologies S.a. has little or no product revenue yet; it used $192m of cash in the twelve months to September 2026. The diluted share count is up 216.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 6 of our 7 financial-health checks.

Our model value for DBV Technologies is under review, so past values are not shown until it is resolved.

Source: 10-Q filed October 28, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 27, 2027 (estimated)

DBV Technologies S.a.'s trailing-twelve-month revenue fell 31.6% year on year, with a free-cash-flow margin of -4997.7%. Where it stands out: long-term debt as % of assets of 0.1% ranks 12 of 78 biotechnology companies we cover. Where it lags: change in share count of 216.3% ranks 155 of 156 biotechnology companies we cover.

Current signal Balance sheet growing far ahead of sales: Total assets grew 95% year over year while revenue fell 32% — the balance sheet is expanding 127 points faster than the business it supports.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.2bn.

Things to watch

  • Revenue shrinking. Revenue fell 31.6% over the last 12 months.
  • Growth slowing. The growth rate is 61.3 points lower than a quarter earlier.
  • Loss-making. Operating margin is -5431.6%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 3188.5 points on a year ago.
  • Burning cash. Free cash flow was -4997.7% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 335.9% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.

Latest results: FY2026 Q3

Filed October 28, 2026
Earnings per share
-$0.13 against an average estimate of -$0.15: beat by 14.9%
Revenue
$2m, down 42.9% on a year earlier
Share reaction
+1.6% in the first session after the results on October 28, 2026, against 0.0% for the S&P 500
Next report
October 28, 2026; average EPS estimate -$0.11

DBV Technologies' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.6%
  • 1 week-9.3%
  • 1 month-14.2%
  • This year-52.8%
  • 1 year-38.2%
  • 5 years+51.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$3.8M
Operating margin
-5431.6%
Net margin
-5405.3%
EPS (TTM, diluted)
$-0.55

Growth

Revenue growth
−31.6%
Change in growth rate
−61.3 pts
Share count change
+216.3%

Cash

Free cash flow (TTM)
-$192M
FCF margin
-4997.7%
Stock pay % of revenue
335.9%

Earnings

Last results
October 28, 2026
Next results (est.)
January 27, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Announcement
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

DBV Technologies S.a. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value DBV Technologies S.a. as an operating company, with every model that fits that kind of business. Cost of equity 10%: the 10-year Treasury yield (4.9%) plus a beta of 1.13 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.9 ~$0.6–$1.3 Left out: out of range vs price (0.10x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.4 ~$0.4–$1.6 Left out: out of range vs price (0.05x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare DBV Technologies S.a. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2019202020212022202320242025Now
Share price$21.40$5.24$3.20$3.06$1.91$3.09$19.17$9.05
Market value$792m$283m$176m$237m$181m$300m$2.7bn$3.4bn
+ Net debt (− = net cash)−$192m−$195m−$77m−$209m−$141m−$32m−$194m−$166m
Enterprise value$600m$88m$99m$28m$40m$267m$2.5bn$3.2bn
Multiples
Price / sales 53.8x25.1x30.8x48.9x11.5x72.2xn/mn/m
Price / earnings ———2.5x2.5x———
Price / free cash flow ————————
EV / EBITDA ————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

8 /100

Weak moat

How hard DBV Technologies's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -50.4% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -2045.2%; its worst year was -8011.3%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -1625.0% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 581.9% over five years; stock-based pay has been a median 50.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.44 +52% $4m −23%
Next −$0.32 +28% $62m +1568%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −7.6% on 90 days ago. In the last 30 days, 0 analysts raised DBV Technologies S.a.'s forecast and 1 cut it.

Consensus EPS forecast DBV Technologies S.a., last 90 days
−$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.47 Current fiscal year, 60 days ago: −$0.47 Current fiscal year, 30 days ago: −$0.46 Current fiscal year, 7 days ago: −$0.44 Current fiscal year, Now: −$0.44 −$0.44 Next fiscal year, 90 days ago: −$0.46 Next fiscal year, 60 days ago: −$0.46 Next fiscal year, 30 days ago: −$0.43 Next fiscal year, 7 days ago: −$0.43 Next fiscal year, Now: −$0.32 −$0.32

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.47−$0.46
60 days ago −$0.47−$0.46
30 days ago −$0.46−$0.43
7 days ago −$0.44−$0.43
Now −$0.44−$0.32

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.15 −$0.13 +14.9%
Jun 2026 −$0.09 −$0.10 −12.0%
Mar 2026 −$0.12 −$0.09 +22.5%
Dec 2025 −$0.19 −$0.20 −5.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

7 analysts, Oct 2026
Buy686%
Hold00%
Sell114%

Monthly trend

  1. Oct 20261517
  2. Sep 20261517
  3. Aug 20261416

Counts of recommendations published by analysts covering DBV Technologies S.a., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
1.4%
of tradable shares
Days to cover
2.42
at average volume
Short interest, 1 month
−36%
to October 15, 2026
Held by institutions
41%
of shares
Held by insiders
0.0%
of shares
Employees
125
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
DBVT−39%−4%−38%+62%+520%−53%
Industry peers (median)−35%−57%−17%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
DBVT33%33%42%25%75%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
DBVT−79%−64%−69%−75%−33%−64%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from October 11, 2017 to November 22, 2024. Getting back needed a 20949% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$8.87 – $24.54
From 52-week high
−63.1%
vs 50-day average
−20.7%
vs 200-day average
−46.5%
Volatility (1 year)
70%
Beta vs S&P 500
0.83

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±5.3%
After a week
4 up, 7 down
typical move ±10.7%
After a month
3 up, 8 down
typical move ±50.9%
Results releasedNext dayS&P 500 next day5 days21 days
October 28, 2026 +1.6% 0.0% — —
July 16, 2026 −6.4% −1.5% −11.8% −10.8%
April 30, 2026 −2.1% +1.3% −1.5% −7.4%
March 26, 2026 −1.3% −3.5% +3.9% +0.6%
October 29, 2025 −9.4% −1.1% −9.3% −15.8%
July 29, 2025 −3.4% −0.4% −0.1% −2.5%
April 30, 2025 −5.2% +0.7% +4.6% −8.0%
March 24, 2025 −19.6% +2.0% +36.7% +85.6%
November 6, 2024 −2.9% +3.3% −18.5% +380.9%
October 22, 2024 −3.0% −1.0% +17.0% −27.5%
July 30, 2024 +5.3% +1.1% −2.2% −5.3%
May 7, 2024 +3.6% +0.1% −11.9% −15.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

DBV Technologies S.a. in five measures

Fundamentals grade E
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) DBV Technologies S.a.
$0 $5M $10M $15M $20M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $15.7M Revenue (TTM), FY24 Q1: $14.9M Revenue (TTM), FY24 Q2: $13.8M Revenue (TTM), FY24 Q3: $12.5M Revenue (TTM), FY24 Q4: $4.2M Revenue (TTM), FY25 Q1: $3.5M Revenue (TTM), FY25 Q2: $3.9M Revenue (TTM), FY25 Q3: $5.6M Revenue (TTM), FY25 Q4: $5.7M Revenue (TTM), FY26 Q1: $5.8M Revenue (TTM), FY26 Q2: $5M Revenue (TTM), FY26 Q3: $3.8M $3.8M

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $15.7M
FY24 Q1 $14.9M
FY24 Q2 $13.8M
FY24 Q3 $12.5M
FY24 Q4 $4.2M
FY25 Q1 $3.5M
FY25 Q2 $3.9M
FY25 Q3 $5.6M
FY25 Q4 $5.7M
FY26 Q1 $5.8M
FY26 Q2 $5M
FY26 Q3 $3.8M
Revenue growth, TTM YoY DBV Technologies S.a.
-100% 0% 100% 200% 300% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 224.6% Revenue growth, TTM YoY, FY24 Q1: 232.6% Revenue growth, TTM YoY, FY24 Q2: 163.0% Revenue growth, TTM YoY, FY24 Q3: 125.5% Revenue growth, TTM YoY, FY24 Q4: -73.6% Revenue growth, TTM YoY, FY25 Q1: -76.3% Revenue growth, TTM YoY, FY25 Q2: -71.9% Revenue growth, TTM YoY, FY25 Q3: -55.2% Revenue growth, TTM YoY, FY25 Q4: 38.2% Revenue growth, TTM YoY, FY26 Q1: 64.7% Revenue growth, TTM YoY, FY26 Q2: 29.7% Revenue growth, TTM YoY, FY26 Q3: -31.6% -31.6%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 224.6%
FY24 Q1 232.6%
FY24 Q2 163.0%
FY24 Q3 125.5%
FY24 Q4 -73.6%
FY25 Q1 -76.3%
FY25 Q2 -71.9%
FY25 Q3 -55.2%
FY25 Q4 38.2%
FY26 Q1 64.7%
FY26 Q2 29.7%
FY26 Q3 -31.6%
Operating margin (TTM) DBV Technologies S.a.
-6000% -4000% -2000% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -485.9% Operating margin (TTM), FY24 Q1: -561.0% Operating margin (TTM), FY24 Q2: -670.2% Operating margin (TTM), FY24 Q3: -836.2% Operating margin (TTM), FY24 Q4: -2808.7% Operating margin (TTM), FY25 Q1: -3234.5% Operating margin (TTM), FY25 Q2: -3139.0% Operating margin (TTM), FY25 Q3: -2243.1% Operating margin (TTM), FY25 Q4: -2563.7% Operating margin (TTM), FY26 Q1: -2884.8% Operating margin (TTM), FY26 Q2: -3531.7% Operating margin (TTM), FY26 Q3: -5431.6% -5431.6%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -485.9%
FY24 Q1 -561.0%
FY24 Q2 -670.2%
FY24 Q3 -836.2%
FY24 Q4 -2808.7%
FY25 Q1 -3234.5%
FY25 Q2 -3139.0%
FY25 Q3 -2243.1%
FY25 Q4 -2563.7%
FY26 Q1 -2884.8%
FY26 Q2 -3531.7%
FY26 Q3 -5431.6%
FCF margin (TTM) DBV Technologies S.a.
-6000% -4000% -2000% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -510.7% FCF margin (TTM), FY24 Q1: -638.5% FCF margin (TTM), FY24 Q2: -763.6% FCF margin (TTM), FY24 Q3: -868.7% FCF margin (TTM), FY24 Q4: -2573.2% FCF margin (TTM), FY25 Q1: -2553.2% FCF margin (TTM), FY25 Q2: -2281.2% FCF margin (TTM), FY25 Q3: -1752.4% FCF margin (TTM), FY25 Q4: -2121.9% FCF margin (TTM), FY26 Q1: -2596.2% FCF margin (TTM), FY26 Q2: -3387.9% FCF margin (TTM), FY26 Q3: -4997.7% -4997.7%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -510.7%
FY24 Q1 -638.5%
FY24 Q2 -763.6%
FY24 Q3 -868.7%
FY24 Q4 -2573.2%
FY25 Q1 -2553.2%
FY25 Q2 -2281.2%
FY25 Q3 -1752.4%
FY25 Q4 -2121.9%
FY26 Q1 -2596.2%
FY26 Q2 -3387.9%
FY26 Q3 -4997.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 15 11 6 5 16 4 6 4
EBITDA — −154 −94 −94 −73 −114 −144 —
Operating income −171 −159 −99 −97 −76 −117 −147 −208
Net income −172 −160 −98 96 73 −114 −147 −207
Diluted EPS −$4.65 −$2.95 −$1.78 −$1.24 −$0.76 −$1.17 −$1.05 −$0.55
Growth (year on year)
Revenue — −23.3% −49.4% −15.1% +224.7% −73.6% +35.8% −31.6%
Net income — — — — −24.5% −256.7% — —
Margins
EBITDA margin — <−999% <−999% <−999% −463.3% <−999% <−999% —
Operating margin <−999% <−999% <−999% <−999% −486.0% <−999% <−999% <−999%
Net margin <−999% <−999% <−999% >999% 462.3% <−999% <−999% <−999%
Free-cash-flow margin <−999% <−999% <−999% <−999% −510.7% <−999% <−999% <−999%
Cash flow
Cash from operations −148 −166 −108 −56 −80 −104 −121 −188
Capital spending 6 3 1 1 1 2 1 3
Free cash flow −154 −168 −109 −56 −80 −107 −122 −192
Stock-based pay 17 −1 3 5 6 5 5 13
Free cash flow after stock pay −171 −167 −112 −61 −86 −111 −127 −205
Balance sheet
Cash 193 196 77 209 141 32 194 166
Total debt 1 1 1 — 0 0 0 0
Net debt (negative = net cash) −192 −195 −77 −209 −141 −32 −194 −166
Diluted shares 37m 54m 55m 77m 95m 97m 140m 374m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

6 of 7 checks passed · September 30, 2026
What it owns · $215m
Short-term assets $190mLonger-term assets $26m
What it owes, and who funded it · $215m
Short-term liabilities $59mLonger-term liabilities $8mShareholders' equity $149m
  • Short-term assets cover short-term liabilities $190m of assets due within a year against $58m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $190m short-term assets against $8m of longer-dated liabilities.
  • More cash than debt $166m of cash against $200,000 of debt.
  • Debt below 40% of shareholders' equity Debt is 0% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 1% to 0% over five years.
  • A year's operating cash flow covers at least 20% of debt −$188m of operating cash flow against $200,000 of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From DBV Technologies S.a.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+216.3%
year over year
R&D spending
3766.5%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated DBVT DYAI ALGS CAMP CRIS ENSC Median
Revenue, last 12 months $4m $4m $4m $4m $4m $5m $56m
Revenue growth, last 12 months −31.6% −8.0% 19.4% 40.2% −62.2% −39.3% 12.6%
Revenue growth, 3-year average −11.6% 3.4% −5.5% — −25.0% 14.6% 13.7%
Revenue growth, latest quarter −42.9% −0.6% −100.0% 18.8% −100.0% −15.1% 10.2%
Operating margin <−999% −195.1% <−999% <−999% −203.2% −281.3% −189.4%
Operating margin, 3-year average <−999% −257.9% <−999% — −341.2% −347.6% −363.5%
Net margin <−999% −200.5% <−999% <−999% −490.3% −280.5% −169.8%
Cash from operations / revenue <−999% −194.7% <−999% −678.2% −709.0% −196.8% −168.0%
Free-cash-flow margin <−999% — <−999% −681.2% −709.0% −197.2% −162.4%
Free-cash-flow margin, 3-year average <−999% — <−999% — −465.5% −165.8% −310.0%
Stock pay / revenue 335.9% 17.1% 149.8% 131.4% 66.4% 1.8% 20.0%
Change in share count 216.3% 20.3% 30.7% — 90.7% 74.6% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -31.6% 12.6% 132 of 172
Change in growth rate Growth -61.3pp -0.1pp 148 of 172
Operating margin Profitability -5431.6% -189.4% 160 of 175
Net margin Profitability -5405.3% -157.3% 166 of 180
Free-cash-flow margin Cash generation -4997.7% -145.4% 163 of 176
Stock pay as % of revenue Cash generation 335.9% 19.2% 159 of 179
Long-term debt as % of assets Balance sheet 0.1% 20.6% 12 of 78
Change in share count Balance sheet 216.3% 7.9% 155 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$344M
Institutions reporting
77
Shares held vs prior quarter
▲ 1.7%
Positions opened / closed
17 / 10

Top buyers and sellers, Q2 2026: 34 institutions bought and 34 sold ; the biggest buyer was UBS Group AG (+1.2M shares) and the biggest seller Mpm Bioimpact LLC (−1.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Mpm Bioimpact LLC $60.1M 3.7M 17.5% ▼ 29.7%
Siren, L.L.C. $30.5M 1.9M 8.9% 0.0%
Vivo Capital, LLC $30.3M 1.8M 8.8% ▼ 30.8%
Perceptive Advisors LLC $27.1M 1.7M 7.9% ▲ 71.4%
Baker Bros. Advisors LP $24M 1.5M 7.0% 0.0%
Artisan Partners Limited Partnership $22.5M 1.4M 6.5% ▼ 38.1%
UBS Group AG $21.5M 1.3M 6.3% ▲ 1551.4%
Morgan Stanley $15.7M 955K 4.6% ▲ 553.5%
Logos Global Management LP $15M 915K 4.4% New
Patient Square Capital LP $14.9M 909K 4.3% ▲ 31.1%
Octagon Capital Advisors LP $9.4M 574K 2.7% 0.0%
ADAR1 Capital Management, LLC $8.7M 528K 2.5% ▼ 47.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not DBV Technologies S.a.'s complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $15.5M 7 trades by 2 insiders · 0% under pre-set plans
Net ▼ $15.5M net selling
Insider Date Trade Shares Price Value
Mohideen Pharis Chief Medical Officer July 29, 2026 Sell 464 $2.70 $1,253
Mohideen Pharis Chief Medical Officer January 29, 2026 Sell 534 $4.86 $2,595
Epic Bpifrance 10% owner December 18, 2025 Sell 1,292,103 $4.19 $5.4M
Epic Bpifrance 10% owner December 17, 2025 Sell 40,000 $5.28 $211,200
Epic Bpifrance 10% owner December 17, 2025 Sell 2,036,990 $4.84 $9.9M
Mohideen Pharis Chief Medical Officer November 21, 2025 Sell 1,624 $2.77 $4,498
Mohideen Pharis Chief Medical Officer November 20, 2025 Sell 6,496 $2.88 $18,708

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 27, 2027 estimated from the company's past filing pattern, not announced

  • October 28, 2026
  • July 16, 2026
  • April 30, 2026
  • March 26, 2026
  • October 29, 2025
  • July 29, 2025

Recent SEC filings

Data status

When each part of this page on DBV Technologies S.a. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

DBV Technologies S.a. in brief

What does DBV Technologies S.a. do?
DBV Technologies S.a. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is DBV Technologies S.a.'s stock ticker?
DBV Technologies S.a. trades under the ticker DBVT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is DBV Technologies S.a.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, DBV Technologies S.a. reported revenue of $3.8M, 31.6% lower than a year earlier, according to its SEC filings.
What is DBV Technologies S.a.'s free cash flow?
DBV Technologies S.a.'s free-cash-flow margin is -4997.7% of revenue over the trailing twelve months, ranking 163 of the 176 biotechnology companies we cover.
Who are DBV Technologies S.a.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Mpm Bioimpact LLC, Siren, L.L.C. and Vivo Capital, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is DBV Technologies S.a.'s market cap?
On November 2, 2026, DBV Technologies S.a.'s market capitalisation was about $3.4B and net debt of -$166M. Market figures come from third-party market data and may be delayed.
How much debt does DBV Technologies S.a. have?
DBV Technologies S.a.'s debt-to-equity ratio is 0.1%, from its latest balance sheet (0.6% five years earlier). The financial health section below sets out its other solvency checks.
Who are DBV Technologies S.a.'s competitors?
In our Biotechnology peer group, the companies closest to DBV Technologies S.a. are Dyadic International Inc, Aligos Therapeutics, Inc., Camp4 Therapeutics Corp, Curis Inc and Ensysce Biosciences, Inc. The side-by-side comparison below sets their revenue, margins and growth against DBV Technologies S.a.'s.
Are insiders buying or selling DBV Technologies S.a. stock?
Over the last 12 months, DBV Technologies S.a.'s directors and officers reported 0 open-market purchases and 7 sales on Form 4. The insider trading page charts every trade.
When is DBV Technologies S.a.'s next earnings date?
Around January 27, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — DBV Technologies S.a. announces its own schedule.